Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranolazine in HFpEF (RALI-DHF)
NCT01163734Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Apr 2010
- Primary completion
- Feb 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ranolazine in heart failure with preserved ejection fraction (HFpEF), sponsored by Gilead Sciences. Started Apr 2010; status: completed.
02
Drugs
ranolazine
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT01163734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01163734.